13F filer · CIK 873687 ↗
Northwestern University
You are looking at Q3 2025. See the latest, Q3 2026 →
Reported value
$56.6M
+0.2% on the quarter before
Positions
4
0 new · 0 sold out
Top 10
100.0%
of the value
Est. gain
+$264,891
on stocks held all quarter
Est. return
+0.5%
on those stocks since Q2 2025
Positions as of Sep 30, 2025, from Northwestern University's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2025. Striped tiles are options.
Largest buys
Since Q2 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
No buys this quarter.
Largest sells
Since Q2 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Actuate Therapeutics Inc~$142,431Cut · 0.3% → 0.1%−21,290 shares
Holdings
As of Sep 30, 2025. Changes are in shares against Jun 30, 2025, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Berkshire Hathaway Inc DelCL A · shares 0% · price +3.5% | 88.0% | $49.8M | +$1.7M | ||||||||
| Ryan Specialty Holdings IncCL A · shares 0% · price −17.1% | 11.9% | $6.7M | −$1.4M | ||||||||
| Actuate Therapeutics IncCOM · shares −77% · price +9.5% | 0.08% | $43,405 | +$3,764 | ||||||||
| Exicure IncCOM · shares 0% · price −41.9% | 0.08% | $42,659 | −$30,768 | ||||||||
| Total · 4 positions | 100% | $56.6M | +$264,891 |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2025 to Q3 2025: 4 stocks held throughout, up $264,891 (+0.5%).
- Berkshire Hathaway Inc Del+$1.7M+3%
- Actuate Therapeutics Inc+$3,764+9%
- Exicure Inc−$30,768−42%
- Ryan Specialty Holdings Inc−$1.4M−17%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2026 | Oct 21, 2026 | $64.5M+2% | SEC ↗ |
| Q2 2026 | Jul 9, 2026 | $63.3M+23% | SEC ↗ |
| Q1 2026 | Apr 16, 2026 | $51.5M−51% | SEC ↗ |
| Q4 2025 | Jan 26, 2026 | $105.7M+87% | SEC ↗ |
| Q3 2025 | Oct 29, 2025 | $56.6M+0% | SEC ↗ |
| Q2 2025 | Jul 16, 2025 | $56.4M−10% | SEC ↗ |
| Q1 2025 | Apr 16, 2025 | $62.5M+0% | SEC ↗ |
| Q4 2024 | Jan 28, 2025 | $62.4M−27% | SEC ↗ |
| Q3 2024 | Nov 12, 2024 | $85.1M−8% | SEC ↗ |
| Q2 2024 | Jul 29, 2024 | $92.8M−14% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $107.7M−4% | SEC ↗ |
| Q4 2023 | Jan 11, 2024 | $112.2M−13% | SEC ↗ |
| Q3 2023 | Oct 30, 2023 | $129.3M+27% | SEC ↗ |
| Q2 2023 | Jul 25, 2023 | $102.0M−9% | SEC ↗ |
| Q1 2023 | May 1, 2023 | $112.2M+8% | SEC ↗ |
| Q4 2022 | Jan 26, 2023 | $104.3M+3% | SEC ↗ |
| Q3 2022 | Oct 19, 2022 | $101.6M+6% | SEC ↗ |
| Q2 2022 | Jul 13, 2022 | $95.4M−21% | SEC ↗ |
| Q1 2022 | May 19, 2022 | $120.6M+10% | SEC ↗ |
| Q4 2021 | Feb 1, 2022 | $109.3M+7% | SEC ↗ |
| Q3 2021 | Oct 26, 2021 | $102.5M−15% | SEC ↗ |
| Q2 2021 | Jul 27, 2021 | $120.2M+31% | SEC ↗ |
| Q1 2021 | May 4, 2021 | $91.7M−38% | SEC ↗ |
| Q4 2020 | Jan 29, 2021 | $147.8M−11% | SEC ↗ |
| Q3 2020 | Oct 28, 2020 | $165.8M+9% | SEC ↗ |
| Q2 2020 | Aug 4, 2020 | $152.0M+3% | SEC ↗ |
| Q1 2020 | Apr 30, 2020 | $147.1M−29% | SEC ↗ |
| Q4 2019 | Feb 5, 2020 | $205.8M+7% | SEC ↗ |
| Q3 2019 | Oct 31, 2019 | $192.4M−4% | SEC ↗ |
| Q2 2019 | Aug 6, 2019 | $199.7M+21% | SEC ↗ |
| Q1 2019 | May 8, 2019 | $164.9M+4% | SEC ↗ |
| Q4 2018 | Feb 4, 2019 | $157.8M−6% | SEC ↗ |
| Q3 2018 | Nov 5, 2018 | $168.5M+12% | SEC ↗ |
| Q2 2018 | Aug 9, 2018 | $151.1M−44% | SEC ↗ |
| Q1 2018 | May 10, 2018 | $269.4M+21% | SEC ↗ |
| Q4 2017 | Jan 22, 2018 | $221.8M+54% | SEC ↗ |
| Q3 2017 | Nov 1, 2017 | $143.8M+8% | SEC ↗ |
| Q2 2017 | Aug 9, 2017 | $133.0M+1% | SEC ↗ |
| Q1 2017 | May 1, 2017 | $131.6M+0% | SEC ↗ |
| Q4 2016 | Feb 3, 2017 | $131.5M−2% | SEC ↗ |
| Q3 2016 | Nov 8, 2016 | $134.5M+16% | SEC ↗ |
| Q2 2016 | Jul 25, 2016 | $115.6M+3% | SEC ↗ |
| Q1 2016 | Apr 26, 2016 | $112.3M | SEC ↗ |